Market capitalization | $638.03m |
Enterprise Value | $374.43m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 2.69 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-168.35m |
Free Cash Flow (TTM) Free Cash Flow | $-128.55m |
Cash position | $263.60m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
7 Analysts have issued a Mineralys Therapeutics forecast:
7 Analysts have issued a Mineralys Therapeutics forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.03 -0.03 |
-
|
|
EBITDA | -168 -168 |
151%
151%
|
EBIT (Operating Income) EBIT | -168 -168 |
151%
151%
|
Net Profit | -153 -153 |
171%
171%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Mineralys Therapeutics, Inc. s a clinical-stage biopharmaceutical company engaged in developing medicines to target disease, driven by abnormally elevated aldosterone. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
Head office | United States |
CEO | Jon Congleton |
Employees | 28 |
Founded | 2019 |
Website | www.mineralystx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.